Search

Showing "11155" results for ""

Recent news at aidsmap.com

HIV treatment may induce protective immunity in brain, monkey study finds

Brain-penetrating ARVs protect against death in children

TB treatment guidelines need to change, systematic reviews show

Raltegravir approved for first-line use in European Union

Switches to second-line ART occurring faster where viral load testing available

GSK's second integrase inhibitor looks potent and well-tolerated in early study

Number of UK gay men ever tested rises to two-thirds

Nutritional formula linked to reduced CD4 cell loss in untreated people

Pregnancy registry shows no evidence that tenofovir causes birth defects

IL-7 may boost CD4 and CD8 T-cells, study shows

Mental health and HIV: a clinical review

Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression

Once-daily Kaletra approved in the European Union

Boosted protease inhibitor regimens with 3TC work despite M184V resistance

Maturation inhibitor bevirimat is well tolerated and effective in predicted responders

GS-9350 boosts atazanavir just as well as ritonavir

Tobacco, marijuana and alcohol may lower levels of some anti-HIV drugs

Receive the latest HIV research and conference news

Showing "11155" results for ""

Recent news at aidsmap.com

HIV treatment may induce protective immunity in brain, monkey study finds

Brain-penetrating ARVs protect against death in children

TB treatment guidelines need to change, systematic reviews show

Raltegravir approved for first-line use in European Union

Switches to second-line ART occurring faster where viral load testing available

GSK's second integrase inhibitor looks potent and well-tolerated in early study

Number of UK gay men ever tested rises to two-thirds

Nutritional formula linked to reduced CD4 cell loss in untreated people

Pregnancy registry shows no evidence that tenofovir causes birth defects

IL-7 may boost CD4 and CD8 T-cells, study shows

Mental health and HIV: a clinical review

Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression

Once-daily Kaletra approved in the European Union

Boosted protease inhibitor regimens with 3TC work despite M184V resistance

Maturation inhibitor bevirimat is well tolerated and effective in predicted responders

GS-9350 boosts atazanavir just as well as ritonavir

Tobacco, marijuana and alcohol may lower levels of some anti-HIV drugs

Receive the latest HIV research and conference news